By Adriano Marchese
Opsens said Tuesday that it has agreed to be acquired by healthcare company Haemonetics in a deal worth 345 million Canadian dollars, or about $253.9 million, following a strategic review.
The Canadian manufacturer of fiber optic sensors said that Boston, Mass.-based Haemonetics and its wholly owned subsidiary will offer C$2.90 a share in cash for the acquisition.
This is a 50% premium to Opsens' closing price on Friday, its last trading day, which closed at C$1.93 a share.
The stock has edged forward by about 2.7% in 2023, but is still down 24% over the last 12 months.
Opsens said it expects the synergies between its portfolio and Haemonetics' hospital-based products will drive improvements in patient care.
The company added that its expertise in research and development, as well as in production, will complement Haemonetics' commercial and manufacturing scale and help drive adoption of products globally.
Executive Chairman Alan Milinazzo said the deal is in the best interests of the company and its shareholders after a substantial strategic review.
The transaction is expected to close by the end of January 2024.